Contact Us
Arthur Roach
Arthur has directed research into new treatments for Parkinson’s and other brain conditions at top ten pharma companies (BMS, DuPont Merck, Merk Serono) and is currently completing ten years as Director of the Research and Virtual Biotech programmes at Parkinson’s UK.
Arthur founded Chord Theraputics in 2013 and led it through seed and Series A funding rounds to a successful exit in 2022. He has a doctorate in molecular biology and biochemistry from Caltech and conducted neuroscience research at Cornell University Medical College and University of Toronto’s Department of Medical and Molecular Genetics.
Arthur created the seed investment programme at Parkinson’s UK in 2016 (the “Parkinson’s Virtual Biotech”) leading a team that has invested £30m in 17 drug discovery and development opportunities, in the UK, US and elsewhere.
Felicity Percy
Felicity is an experienced fund manager with over 25 years experience in the asset management industry. Most recently a Managing Director at BlackRock, Felicity has extensive experience in creating, launching and managing a wide range of different investment vehicles, with expertise in product development, fixed income, scientific investing, index strategies, and sustainable investing. She has worked with a vast range of different clients, institutions and investors over many years to develop new and innovative investment opportunities to meet their unique goals. Felicity has a MSc in Development Economics from LSE.
Felicity has various family connections to Parkinson’s Disease and has been a keen observer of scientific and clinical development in this field for 30 years. She has been a supporter of Parkinson’s Virtual Biotech since its launch.